Developer docs
API playgroundTry for free, no card

Search company profiles

Qbtech

Full company profile

uuid0006ukc

Namestring
Qbtech
Legal namestring
Qbtech AB
Websiteurl
qbtech.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Qbtech AB is a Swedish medical-technology company founded in 2000 (incorporated 2002) by the Gillberg family and psychologist Fredrik Ulberstad, headquartered in Stockholm with wholly-owned subsidiaries in the United States, the United Kingdom, and Germany. The company develops FDA-cleared, NICE-recommended objective diagnostic and treatment-monitoring technology for ADHD, anchored on two core products: QbTest, an in-clinic hardware-based test using a headband and motion-tracking camera, and QbCheck, a web-based test deliverable in-clinic or remotely. Both measure the three core ADHD symptoms — hyperactivity, impulsivity, and inattention — and compare results to age- and sex-at-birth-matched normative data drawn from over one million test takers globally.

The product portfolio is completed by QbClinic (clinician administration portal), QbPath (patient-facing portal), QbMobile (smartphone-based assessment launched 2025), QbAdmin, and QbAcademy (digital training). Qbtech monetizes through two primary streams: per-test credits on the Growth plan starting at £65 / $68 / €75 per test, and tailored multi-year enterprise subscriptions with dedicated Customer Success Managers, API integrations, and per-patient or per-test billing. Distribution is direct via enterprise field sales and inside sales, supported by a team of clinical advisors.

Qbtech serves five primary verticals — virtual care providers, primary care, specialist care, private healthcare, and education — across 18 countries, with the NHS Focus ADHD national programme in England (70% of child clinics) and named customers including ADHD360, Legion Health, and Meridian Advanced Psychiatry. The company has secured four FDA 510(k) clearances, MDR certification, CE marking, and ISO 13485 and ISO 27001 certifications. Verdane invested as a growth-equity partner in 2022. Qbtech reports over 35,000 clinicians using its technology globally.

Short descriptiontext

Qbtech develops FDA-cleared, NICE-recommended objective ADHD diagnostic technology (QbTest, QbCheck, QbMobile) used by 35,000+ clinicians across 18 countries to measure hyperactivity, impulsivity, and inattention.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
objective ADHD testing, medical diagnostic software, ADHD assessment technology, computerized cognitive testing, mental health diagnostics
Industry2 codes
PRIMARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Prepackaged Software7372
Product category
ADHD Diagnostics Software
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1QbCheck Software Subscription (Growth Plan)
TypeUsage Based
Description

Per-test credits model with invoicing upfront. Test credits valid for 12 months from purchase date. Automatic renewal when test credits are used. Starting from £65 / $68 / €75 per test for the Growth tier.

qbtech.com
2QbCheck Enterprise Plans
TypeSubscription Recurring
Description

Tailored plans for at-scale providers with features including QbClinic test administrator, dedicated Customer Success Manager, expert training, self-guided learning modules, API integrations, and per patient or per test billing options.

qbtech.com
3QbTest Hardware and Subscription
TypeSubscription Recurring
Description

In-clinic testing solution with hardware components (headband, motion-tracking camera, and stand) combined with subscription for unlimited clinical user accounts and instantly generated reports. Includes secure end-to-end encryption.

qbtech.com
4Professional Services and Training
TypeProfessional Services
Description

Comprehensive onboarding, onsite training, on-request weekday support, and interactive training sessions with clinical experts included as part of product deployment.

qbtech.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details3 tiers
1Growth Plan - For clinics seeking assured growth
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Starting from £65 / $68 / €75 per test. Includes QbCheck objective ADHD test and rating scales, clinician portal & training resources, patient portal & test guidance, baseline vs retest comparison report, and interactive training sessions with clinical experts. Purchase invoiced upfront with 12-month validity on test credits.

qbtech.com
2Enterprise Plan - Tailored plan for at-scale providers
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Custom pricing based on clinic requirements. Includes QbCheck objective ADHD test and rating scales, QbClinic test administrator, dedicated Customer Success Manager, expert training tailored to needs, self-guided learning modules, optimized patient flow, API integrations, and per patient or per test billing options. Contact sales for pricing.

qbtech.com
3QbTest - In-clinic hardware-based testing
ModelSubscriptionBilling cadenceAnnual
Notes

Includes unlimited clinical user accounts, headband, motion-tracking camera and stand, instantly generated reports and retest comparisons, and secure end-to-end encryption. Pricing not publicly disclosed - requires contact with sales team.

qbtech.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1QbCheck
Description

Flexible at-home and in-clinic FDA-cleared ADHD test for children and adults (ages 6-60). Web-based objective ADHD testing platform with remote and in-clinic testing capabilities.

qbtech.com
+3 more records
Core offering1 text field

Qbtech provides FDA-cleared, MDR-certified objective ADHD testing technology for healthcare providers. Its core offerings include QbTest, an in-clinic hardware-based assessment, and QbCheck, a web-based test usable remotely or in-clinic. Both products measure the three core ADHD symptoms (hyperactivity, impulsivity, inattention) using computerized attention-based tasks combined with motion tracking, comparing results to age- and sex-matched normative control groups.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 13 values shown
  • 44% reduction in time to diagnostic decision (AQUA study)
+12 more records
Product overview1 text field

Qbtech offers a portfolio of clinically validated ADHD diagnostic and monitoring solutions centered on two FDA-cleared objective tests: QbTest (in-clinic hardware-based assessment) and QbCheck (flexible web-based platform usable in-clinic or remotely). These core products are supported by complementary platforms including QbClinic (clinician admin portal), QbPath (patient-facing portal for test completion), and QbAcademy (digital training). The portfolio measures the three core ADHD symptoms—hyperactivity, impulsivity, and inattention—through computerized tasks combined with motion tracking, comparing results to age and sex-matched normative data. All products are designed for use by clinicians in primary care, specialist care, virtual care, private practice, and educational settings.

Product and service7 records
1QbTest
CategoryADHD Diagnostic Software
Description

FDA-cleared in-clinic ADHD assessment tool for individuals aged 6-60 that objectively measures hyperactivity, impulsivity, and inattention using hardware (headband and motion-tracking camera) combined with software. The 20-minute computer-based test tracks motor activity with 1mm precision and compares results to age and sex-matched normative data.

2QbCheck
CategoryADHD Diagnostic Software
Description

FDA-cleared, MDR-certified, CE-marked web-based ADHD test equivalent to QbTest but with increased flexibility and no hardware dependency. Can be administered in-clinic or remotely via the QbPath patient portal, with results compared to normative control groups. Includes integrated rating scales and supports treatment monitoring.

3QbClinic
CategoryClinical Workflow Platform
Description

Clinician administration portal for QbCheck that enables management of patient profiles, multi-site clinics, test progress, reports, and access to support resources. Allows clinicians to assign objective tests and subjective assessments as a single task.

4QbPath
CategoryPatient Portal
Description

Patient-facing portal for completing QbCheck assessments. Provides step-by-step video instructions, task tracking, and enables secure automatic collection of rating scales from parents or teachers. Supports both remote and in-clinic testing scenarios.

5QbMobile
CategoryADHD Diagnostic Software
Description

Smartphone-based application for clinical assessment of ADHD, enabling objective measurement of attention deficit hyperactivity disorder using mobile devices.

6QbAcademy
CategoryTraining Platform
Description

Digital learning platform offering bite-size training videos and quizzes for both QbCheck and QbTest users, supporting self-paced onboarding and ongoing education for clinicians.

7QbAdmin
CategoryClinical Workflow Platform
Description

Administration portal for QbTest (as distinguished from QbClinic which is used for QbCheck), providing test administration and report access for in-clinic testing.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

QbCheck integrated into the CHIRP clinical workflow in New Zealand, combining paediatrics, child development services and child and adolescent mental health services.

2ADHD Expert Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Coalition of healthcare professionals including psychiatrists, psychologists, neurologists, developmental pediatricians, and patient advocates formed to advocate for improved ADHD care standards and evidence-based objective testing as standard of care.

qbtech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

QbTest selected as one of 11 innovations to join the NHS Innovation Accelerator, supporting spread of innovation across NHS England. This led to the Focus ADHD national programme.

4AHSN Network (Academic Health Science Network)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Partnership with AHSN Network for Focus ADHD national programme. Resulted in 70% of child clinics in England including QbTest. Awarded 'Best Mental Health Partnership with the NHS' in 2022 and 'Innovate Awards - Innovation Spread' in 2023.

qbtech.com
5Gillberg Family
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2002-01-01
Description

The Gillberg family joined forces with leading psychologist Fredrik Ulberstad to launch Qbtech in 2002, bringing clinical research expertise to the company's foundation.

qbtech.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers9 records
1Done
TypeBroad incumbent
Description

Direct-to-consumer virtual ADHD care provider offering diagnosis and stimulant prescribing online. Comparable to Qbtech as a customer/adjacent player: Done represents one of the high-growth virtual ADHD practices that Qbtech sells QbCheck into, and also competes for the same downstream virtual ADHD-assessment workflow.

TypeEmerging player
Description

Digital biomarker company using smartphone-based cognitive and motor tasks augmented with AR/AI for objective brain-function assessment (FDA Breakthrough Device for Alzheimer’s). Comparable to Qbtech in delivering device- and task-based objective brain assessment to clinicians, though focused on neurodegeneration.

TypeBroad incumbent
Description

Digital therapeutic targeting ADHD and cognitive dysfunction (EndeavorRx), FDA-cleared and marketed through clinicians. Same ADHD customer segment and SaMD regulatory posture as Qbtech, but positioned in treatment rather than objective diagnosis.

TypeDirect peer
Description

Digital brain health platform offering tablet/PC-based cognitive assessments (e.g., DCTclock) used by clinicians for early detection and monitoring of cognitive impairment. Comparable to Qbtech in selling clinician-facing digital objective assessments that generate standardized reports.

TypeBroad incumbent
Description

Large US telehealth platform offering ADHD evaluation and treatment among other mental-health conditions. Comparable to Qbtech as both a potential enterprise customer (for embedded objective testing) and a competitor in the virtual ADHD assessment workflow.

TypeEmerging player
Description

Provider of clinician-supervised home neurofeedback and attention-training programs marketed to ADHD patients and clinics. Comparable to Qbtech as a technology-mediated objective ADHD assessment/training option competing for the same clinician and patient mindshare.

TypeBroad incumbent
Description

Established publisher of standardized psychometric and neuropsychological tests (e.g., Q-global platform) widely used for ADHD and learning-disorder assessment. Comparable to Qbtech as a competing objective-adjacent input into ADHD diagnosis, though distributed as traditional psychometric rather than motion-tracking SaMD.

TypeDirect peer
Description

Digital cognitive assessment platform providing clinician-administered, FDA-registered cognitive tests for attention, memory and executive function. Directly comparable to Qbtech because it sells SaaS-based objective cognitive/neuropsych testing to the same healthcare provider and research customer base.

TypeEmerging player
Description

Developer of Mente, an EEG-based home neurofeedback device for ADHD in children. Comparable to Qbtech in targeting the same clinician/patient ADHD population with an objective, technology-driven assessment, but using a different modality (EEG).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qbtech

ADHD Diagnostics Softwareqbtech.com

Qbtech develops FDA-cleared, NICE-recommended objective ADHD diagnostic technology (QbTest, QbCheck, QbMobile) used by 35,000+ clinicians across 18 countries to measure hyperactivity, impulsivity, and inattention.

What Qbtech does

Qbtech AB is a Swedish medical-technology company founded in 2000 (incorporated 2002) by the Gillberg family and psychologist Fredrik Ulberstad, headquartered in Stockholm with wholly-owned subsidiaries in the United States, the United Kingdom, and Germany. The company develops FDA-cleared, NICE-recommended objective diagnostic and treatment-monitoring technology for ADHD, anchored on two core products: QbTest, an in-clinic hardware-based test using a headband and motion-tracking camera, and QbCheck, a web-based test deliverable in-clinic or remotely. Both measure the three core ADHD symptoms — hyperactivity, impulsivity, and inattention — and compare results to age- and sex-at-birth-matched normative data drawn from over one million test takers globally.

The product portfolio is completed by QbClinic (clinician administration portal), QbPath (patient-facing portal), QbMobile (smartphone-based assessment launched 2025), QbAdmin, and QbAcademy (digital training). Qbtech monetizes through two primary streams: per-test credits on the Growth plan starting at £65 / $68 / €75 per test, and tailored multi-year enterprise subscriptions with dedicated Customer Success Managers, API integrations, and per-patient or per-test billing. Distribution is direct via enterprise field sales and inside sales, supported by a team of clinical advisors.

Qbtech serves five primary verticals — virtual care providers, primary care, specialist care, private healthcare, and education — across 18 countries, with the NHS Focus ADHD national programme in England (70% of child clinics) and named customers including ADHD360, Legion Health, and Meridian Advanced Psychiatry. The company has secured four FDA 510(k) clearances, MDR certification, CE marking, and ISO 13485 and ISO 27001 certifications. Verdane invested as a growth-equity partner in 2022. Qbtech reports over 35,000 clinicians using its technology globally.

Qbtech firmographics

Firmographics
Name
Qbtech
Legal name
Qbtech AB
Website
https://qbtech.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Qbtech develops FDA-cleared, NICE-recommended objective ADHD diagnostic technology (QbTest, QbCheck, QbMobile) used by 35,000+ clinicians across 18 countries to measure hyperactivity, impulsivity, and inattention.
Ownership category
akta.pro rank

Qbtech industry classification

Industry
Product category
ADHD Diagnostics Software
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories

Keywords

  • Objective ADHD testing
  • Medical diagnostic software
  • ADHD assessment technology
  • Computerized cognitive testing
  • Mental health diagnostics

Where Qbtech is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices4 records

Markets served

Qbtech business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. QbCheck Software Subscription (Growth Plan): Per-test credits model with invoicing upfront. Test credits valid for 12 months from purchase date. Automatic renewal when test credits are used. Starting from £65 / $68 / €75 per test for the Growth tier.
  2. QbCheck Enterprise Plans: Tailored plans for at-scale providers with features including QbClinic test administrator, dedicated Customer Success Manager, expert training, self-guided learning modules, API integrations, and per patient or per test billing options.
  3. QbTest Hardware and Subscription: In-clinic testing solution with hardware components (headband, motion-tracking camera, and stand) combined with subscription for unlimited clinical user accounts and instantly generated reports. Includes secure end-to-end encryption.
  4. Professional Services and Training: Comprehensive onboarding, onsite training, on-request weekday support, and interactive training sessions with clinical experts included as part of product deployment.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGrowth Plan - For clinics seeking assured growth
SubscriptionMulti-year contractEnterprise Plan - Tailored plan for at-scale providers
SubscriptionAnnualQbTest - In-clinic hardware-based testing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels11 records

Qbtech product offering

Product offering

Core offering

Qbtech provides FDA-cleared, MDR-certified objective ADHD testing technology for healthcare providers. Its core offerings include QbTest, an in-clinic hardware-based assessment, and QbCheck, a web-based test usable remotely or in-clinic. Both products measure the three core ADHD symptoms (hyperactivity, impulsivity, inattention) using computerized attention-based tasks combined with motion tracking, comparing results to age- and sex-matched normative control groups.

Product overview

Qbtech offers a portfolio of clinically validated ADHD diagnostic and monitoring solutions centered on two FDA-cleared objective tests: QbTest (in-clinic hardware-based assessment) and QbCheck (flexible web-based platform usable in-clinic or remotely). These core products are supported by complementary platforms including QbClinic (clinician admin portal), QbPath (patient-facing portal for test completion), and QbAcademy (digital training). The portfolio measures the three core ADHD symptoms—hyperactivity, impulsivity, and inattention—through computerized tasks combined with motion tracking, comparing results to age and sex-matched normative data. All products are designed for use by clinicians in primary care, specialist care, virtual care, private practice, and educational settings.

Differentiator

Problem solved

Functional benefit

Brands

  • QbCheck: Flexible at-home and in-clinic FDA-cleared ADHD test for children and adults (ages 6-60). Web-based objective ADHD testing platform with remote and in-clinic testing capabilities.
  • QbTest
  • QbClinic
  • QbPath

Products and services

  • QbTest FDA-cleared in-clinic ADHD assessment tool for individuals aged 6-60 that objectively measures hyperactivity, impulsivity, and inattention using hardware (headband and motion-tracking camera) combined with software. The 20-minute computer-based test tracks motor activity with 1mm precision and compares results to age and sex-matched normative data.
  • QbCheck FDA-cleared, MDR-certified, CE-marked web-based ADHD test equivalent to QbTest but with increased flexibility and no hardware dependency. Can be administered in-clinic or remotely via the QbPath patient portal, with results compared to normative control groups. Includes integrated rating scales and supports treatment monitoring.
  • QbClinic Clinician administration portal for QbCheck that enables management of patient profiles, multi-site clinics, test progress, reports, and access to support resources. Allows clinicians to assign objective tests and subjective assessments as a single task.
  • QbPath Patient-facing portal for completing QbCheck assessments. Provides step-by-step video instructions, task tracking, and enables secure automatic collection of rating scales from parents or teachers. Supports both remote and in-clinic testing scenarios.
  • QbMobile Smartphone-based application for clinical assessment of ADHD, enabling objective measurement of attention deficit hyperactivity disorder using mobile devices.
  • QbAcademy Digital learning platform offering bite-size training videos and quizzes for both QbCheck and QbTest users, supporting self-paced onboarding and ongoing education for clinicians.
  • QbAdmin Administration portal for QbTest (as distinguished from QbClinic which is used for QbCheck), providing test administration and report access for in-clinic testing.

Quantifiable outcome

  • 44% reduction in time to diagnostic decision (AQUA study)
  • +12 more outcomes

Companies that use Qbtech

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Qbtech technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Qbtech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered regional and core.

  • CHIRP (Child Health Integrated Response Pathway) - New ZealandregionalStrategic or Co-development Partner · 1 January 2023QbCheck integrated into the CHIRP clinical workflow in New Zealand, combining paediatrics, child development services and child and adolescent mental health services.
  • ADHD Expert ConsortiumcoreStrategic or Co-development Partner · 1 January 2022Coalition of healthcare professionals including psychiatrists, psychologists, neurologists, developmental pediatricians, and patient advocates formed to advocate for improved ADHD care standards and evidence-based objective testing as standard of care.
  • NHS Innovation Accelerator (NIA)coreStrategic or Co-development Partner · 1 January 2020QbTest selected as one of 11 innovations to join the NHS Innovation Accelerator, supporting spread of innovation across NHS England. This led to the Focus ADHD national programme.
  • AHSN Network (Academic Health Science Network)coreStrategic or Co-development Partner · 1 January 2020Partnership with AHSN Network for Focus ADHD national programme. Resulted in 70% of child clinics in England including QbTest. Awarded 'Best Mental Health Partnership with the NHS' in 2022 and 'Innovate Awards - Innovation Spread' in 2023.
  • Gillberg FamilycoreStrategic or Co-development Partner · 1 January 2002The Gillberg family joined forces with leading psychologist Fredrik Ulberstad to launch Qbtech in 2002, bringing clinical research expertise to the company's foundation.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Qbtech competitors and assessment

Company assessment

Broad incumbents

  • Done: Direct-to-consumer virtual ADHD care provider offering diagnosis and stimulant prescribing online. Comparable to Qbtech as a customer/adjacent player: Done represents one of the high-growth virtual ADHD practices that Qbtech sells QbCheck into, and also competes for the same downstream virtual ADHD-assessment workflow.
  • Akili Interactive: Digital therapeutic targeting ADHD and cognitive dysfunction (EndeavorRx), FDA-cleared and marketed through clinicians. Same ADHD customer segment and SaMD regulatory posture as Qbtech, but positioned in treatment rather than objective diagnosis.
  • Cerebral: Large US telehealth platform offering ADHD evaluation and treatment among other mental-health conditions. Comparable to Qbtech as both a potential enterprise customer (for embedded objective testing) and a competitor in the virtual ADHD assessment workflow.
  • Pearson Clinical Assessments: Established publisher of standardized psychometric and neuropsychological tests (e.g., Q-global platform) widely used for ADHD and learning-disorder assessment. Comparable to Qbtech as a competing objective-adjacent input into ADHD diagnosis, though distributed as traditional psychometric rather than motion-tracking SaMD.

Emerging players

  • Altoida: Digital biomarker company using smartphone-based cognitive and motor tasks augmented with AR/AI for objective brain-function assessment (FDA Breakthrough Device for Alzheimer’s). Comparable to Qbtech in delivering device- and task-based objective brain assessment to clinicians, though focused on neurodegeneration.
  • Myndlift: Provider of clinician-supervised home neurofeedback and attention-training programs marketed to ADHD patients and clinics. Comparable to Qbtech as a technology-mediated objective ADHD assessment/training option competing for the same clinician and patient mindshare.
  • Neurotech International: Developer of Mente, an EEG-based home neurofeedback device for ADHD in children. Comparable to Qbtech in targeting the same clinician/patient ADHD population with an objective, technology-driven assessment, but using a different modality (EEG).

Direct peers

  • Linus Health: Digital brain health platform offering tablet/PC-based cognitive assessments (e.g., DCTclock) used by clinicians for early detection and monitoring of cognitive impairment. Comparable to Qbtech in selling clinician-facing digital objective assessments that generate standardized reports.
  • Creyos: Digital cognitive assessment platform providing clinician-administered, FDA-registered cognitive tests for attention, memory and executive function. Directly comparable to Qbtech because it sells SaaS-based objective cognitive/neuropsych testing to the same healthcare provider and research customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Qbtech social profiles

Digital presence

Qbtech compliance and trust

Trust signal

Compliance7 records

Qbtech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qbtech leadership team

Management profile

Number of profiles

Profiles10 records

Qbtech subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Qbtech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qbtech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qbtech

What does Qbtech do?

Qbtech provides FDA-cleared, MDR-certified objective ADHD testing technology for healthcare providers. Its core offerings include QbTest, an in-clinic hardware-based assessment, and QbCheck, a web-based test usable remotely or in-clinic. Both products measure the three core ADHD symptoms (hyperactivity, impulsivity, inattention) using computerized attention-based tasks combined with motion tracking, comparing results to age- and sex-matched normative control groups.

Is Qbtech a public or private company?

Qbtech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qbtech founded?

Qbtech was founded in 2002. It employs 101 to 250 people.

Where is Qbtech based?

Qbtech is headquartered in Stockholm, Sweden, in the Europe region.

How does Qbtech make money?

Four revenue lines are on record. QbCheck Software Subscription (Growth Plan) is the primary driver. The others are qbCheck Enterprise Plans, qbTest Hardware and Subscription and professional Services and Training.

Who are Qbtech's main competitors?

Broad incumbents on record are Done, Akili Interactive, Cerebral and Pearson Clinical Assessments. Emerging players are Altoida, Myndlift and Neurotech International. Direct peers are Linus Health and Creyos.

Does Qbtech have an API?

Yes. API integrations are available as part of the Enterprise plan, enabling clinics to connect Qbtech's testing platform directly into their existing systems, sync reports into existing records, and standardize processes across teams. Specific API type, authentication method, rate limits, and versioning are not specified in the available source material. Developer documentation is at Not specified.

What industry is Qbtech in?

Qbtech's product category is ADHD Diagnostics Software. Its primary akta.pro industry code is HLAIADAO, Home Diagnostic & Self-Test OTC Kits, with a secondary code of HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Healthcare IT TodayObjective Data for Assessing ADHD from QbtechThe author took Qbtech's FDA-cleared ADHD test, which measures response time and errors, and found his wife had a high likelihood of ADHD. The test provides objective data for clinicians, who can use it to assess medication effectiveness or identify drug seekers.American City Business JournalsHealth tech co. Qbtech opens U.S. HQ in HoustonQbtech, a Swedish health tech company, opened its U.S. headquarters in Houston's Greenway Plaza, moving into a 6,000-square-foot office. The move follows growth from an equity investor, allowing the primarily remote workforce to transition to a physical presence.Business Wire BlogQbtech, Global Leader in Objective ADHD Testing, Opening U.S. Headquarters in HoustonQbtech, a global ADHD testing company, opened a 6,000 sq ft U.S. headquarters in Houston, Texas, to serve as its U.S. operations base. The company has administered over 600,000 objective ADHD assessments, with its tests used by more than 10,000 clinicians globally. A ribbon-cutting ceremony is scheduled for May 24.Business Wire BlogQbtech Partners With Verdane to Accelerate Growth in ADHD Diagnostics Software MarketQbtech, a provider of objective ADHD tests, announced an investment from growth equity firm Verdane. The investment will support new technologies, customer segments, and expansion in existing markets. Qbtech aims to accelerate growth and improve ADHD care access.FrontiersThe Quantified Behavioral Test—A Confirmatory Test in the Diagnostic Process of Adult ADHD?A study of 114 patients at a German outpatient clinic found that the QbTest®, a commercially available continuous performance test marketed by Qbtech, lacks sufficient accuracy to differentiate between adult ADHD patients and those with other psychiatric disorders. While patients with ADHD showed significantly higher motor activity scores on the test, the overall diagnostic accuracy was poor (AUC 65%), and sophisticated ex-Gaussian analysis of reaction times provided no additional discriminative value.PR NewswireQbtech Launches Breakthrough ProductThe US Food and Drug Administration has cleared QbCheck, an online ADHD test developed by Swedish company Qbtech, making it the first objective online ADHD test in the world to receive FDA clearance alongside CE marking. The test, based on the same technology as QbTest which has been used by approximately 250,000 patients, provides objective measurements of hyperactivity, inattention, and impulsivity to support ADHD diagnosis and treatment evaluation. Qbtech plans an initial UK launch in April 2016, followed by expansion to other countries during summer and autumn, targeting new customer groups including primary care providers, schools, and rural healthcare professionals.